Equities research analysts predict that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will report earnings of ($0.25) per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for BioDelivery Sciences International’s earnings. The lowest EPS estimate is ($0.31) and the highest is ($0.20). BioDelivery Sciences International reported earnings of ($0.29) per share in the same quarter last year, which would indicate a positive year over year growth rate of 13.8%. The firm is expected to issue its next quarterly earnings results on Friday, March 16th.

On average, analysts expect that BioDelivery Sciences International will report full-year earnings of $0.14 per share for the current year, with EPS estimates ranging from $0.08 to $0.18. For the next year, analysts anticipate that the business will post earnings of ($0.73) per share, with EPS estimates ranging from ($0.96) to ($0.60). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for BioDelivery Sciences International.

Several equities research analysts have recently commented on the company. Piper Jaffray Companies set a $4.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a research note on Sunday, October 22nd. Roth Capital set a $5.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a research note on Monday, November 13th. Seaport Global Securities assumed coverage on BioDelivery Sciences International in a research note on Friday, January 26th. They issued a “buy” rating and a $5.00 target price for the company. Zacks Investment Research raised BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research note on Wednesday. Finally, HC Wainwright set a $5.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a research note on Monday, November 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $4.38.

In related news, Director Mark A. Sirgo sold 108,000 shares of BioDelivery Sciences International stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $2.57, for a total transaction of $277,560.00. Following the completion of the sale, the director now directly owns 1,759,262 shares of the company’s stock, valued at $4,521,303.34. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Mark A. Sirgo sold 162,509 shares of BioDelivery Sciences International stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $2.78, for a total value of $451,775.02. Following the sale, the director now directly owns 1,759,262 shares of the company’s stock, valued at $4,890,748.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 980,011 shares of company stock valued at $2,666,275. 9.00% of the stock is owned by insiders.

Institutional investors have recently made changes to their positions in the stock. Advisor Group Inc. grew its stake in shares of BioDelivery Sciences International by 42.1% during the second quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock worth $126,000 after purchasing an additional 13,341 shares during the period. Royce & Associates LP acquired a new stake in shares of BioDelivery Sciences International during the third quarter worth $3,814,000. EAM Investors LLC grew its stake in shares of BioDelivery Sciences International by 62.1% during the third quarter. EAM Investors LLC now owns 780,635 shares of the specialty pharmaceutical company’s stock worth $2,303,000 after purchasing an additional 299,163 shares during the period. JPMorgan Chase & Co. acquired a new stake in shares of BioDelivery Sciences International during the third quarter worth $116,000. Finally, Krilogy Financial LLC grew its stake in shares of BioDelivery Sciences International by 28.8% during the third quarter. Krilogy Financial LLC now owns 134,000 shares of the specialty pharmaceutical company’s stock worth $395,000 after purchasing an additional 30,000 shares during the period. 44.16% of the stock is owned by institutional investors and hedge funds.

BioDelivery Sciences International (NASDAQ:BDSI) traded down $0.23 during midday trading on Friday, hitting $2.17. The stock had a trading volume of 476,800 shares, compared to its average volume of 555,823. The firm has a market cap of $134.12, a PE ratio of -11.41 and a beta of 0.50. BioDelivery Sciences International has a one year low of $1.55 and a one year high of $3.60. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.28 and a quick ratio of 1.07.

TRADEMARK VIOLATION WARNING: “” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.chaffeybreeze.com/2018/02/15/1380049.html.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get a free copy of the Zacks research report on BioDelivery Sciences International (BDSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply